Charles Anoopkumar Inderjeeth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Charles Anoopkumar Inderjeeth has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
- Johannes Cornelis Nossent
University of Western Australia Perth Western Australia Australia
37 shared publications - Helen Isobel Keen
Rheumatology Group, School of Medicine, University Western Australia, Perth, Australia
29 shared publications - David Brian Preen
School of Population and Global Health University of Western Australia Perth Western Australia Australia
28 shared publications - Warren Raymond
School of Medicine & Pharmacology
17 shared publications - Khalid Almutairi
School of Medicine, The University of Western Australia, Perth, Australia
12 shared publications Kien Chan
Kien Chan, Bachelor of Medicine and Surgery, FRACP. Department of Geriatric Medicine, Sir Charles Gairdner Hospital, Perth, Australia
8 shared publications
Latest Publications
- 17 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70859
Pregnancy Outcomes for Indigenous Females With Rheumatoid Arthritis in Western Australia
- 17 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70859
Pregnancy Outcomes for Indigenous Females With Rheumatoid Arthritis in Western Australia
- Open Access
- 9 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5390
Dementia and the Impact of Acetylcholinesterase Inhibitors on Falls, Fractures and Mortality in a Geriatric Cohort: A 4-Year Follow-Up Study
Objectives: Dementia and osteoporosis are common and debilitating conditions that often coexist in older adults. We investigated mortality in patients with and without dementia as the primary outcome in a prospective memory clinic cohort. Falls and fractures were assessed as secondary outcomes, and associations with baseline acetylcholinesterase inhibitor (AChEI) use were explored. Methods: In a prospective observational cohort study, data were collected during routine clinical visits over four years. Data included demographics, dementia diagnosis, AChEI use, falls, fractures, bone mineral density (BMD) when clinically available, and mortality. Analysis included chi-square tests, Kaplan–Meier survival curves, Cox proportional hazards models, and recurrent-event models. Because AChEI analyses were exploratory and included several related endpoints, Benjamini–Hochberg false discovery rate (FDR) correction was applied to endpoint-level AChEI p-values. Results: 744 patients were enrolled; the mean age was 80.99 ± 6.8 years; 58.5% female; 55.8% with dementia. AChEI use was recorded in 113 patients (15.2%) at baseline. Over 4 years, 16.61% of participants experienced at least one fall with a cumulative fracture risk of 30.90%. Mortality was significantly higher in dementia patients (44.58% vs. 27.05%; p < 0.001). Dementia patients had double the mortality risk (OR: 1.956; 95% CI: 1.425–2.686). Annual and cumulative mortality rates increased progressively from 5.51% and in year 1 to 17.69% and 36.83% respectively by year 4. Baseline AChEI use was not significantly associated with mortality. Risk/100 for patient with dementia vs. without dementia for falls was 4.04 vs. 4.32 and fracture was 4.37 vs. 3.01. AChEI users had a trend of lower incidence/100 patient-years for falls of 3.01 vs. 4.37 and fractures 6.78 vs. 10.09. Conclusions: Dementia patients have higher mortality risk but not falls or fracture risk in this cohort. Although clinical cohort and animal studies suggest a benefit for AChEIs, this was not evident in this study possibly due to clinical cohort limitations. The trend of reduced falls and fracture in the AChEI cohort warrants further study.
- 9 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5390
Open AccessDementia and the Impact of Acetylcholinesterase Inhibitors on Falls, Fractures and Mortality in a Geriatric Cohort: A 4-Year Follow-Up Study
Objectives: Dementia and osteoporosis are common and debilitating conditions that often coexist in older adults. We investigated mortality in patients with and without dementia as the primary outcome in a prospective memory clinic cohort. Falls and fractures were assessed as secondary outcomes, and associations with baseline acetylcholinesterase inhibitor (AChEI) use were explored. Methods: In a prospective observational cohort study, data were collected during routine clinical visits over four years. Data included demographics, dementia diagnosis, AChEI use, falls, fractures, bone mineral density (BMD) when clinically available, and mortality. Analysis included chi-square tests, Kaplan–Meier survival curves, Cox proportional hazards models, and recurrent-event models. Because AChEI analyses were exploratory and included several related endpoints, Benjamini–Hochberg false discovery rate (FDR) correction was applied to endpoint-level AChEI p-values. Results: 744 patients were enrolled; the mean age was 80.99 ± 6.8 years; 58.5% female; 55.8% with dementia. AChEI use was recorded in 113 patients (15.2%) at baseline. Over 4 years, 16.61% of participants experienced at least one fall with a cumulative fracture risk of 30.90%. Mortality was significantly higher in dementia patients (44.58% vs. 27.05%; p < 0.001). Dementia patients had double the mortality risk (OR: 1.956; 95% CI: 1.425–2.686). Annual and cumulative mortality rates increased progressively from 5.51% and in year 1 to 17.69% and 36.83% respectively by year 4. Baseline AChEI use was not significantly associated with mortality. Risk/100 for patient with dementia vs. without dementia for falls was 4.04 vs. 4.32 and fracture was 4.37 vs. 3.01. AChEI users had a trend of lower incidence/100 patient-years for falls of 3.01 vs. 4.37 and fractures 6.78 vs. 10.09. Conclusions: Dementia patients have higher mortality risk but not falls or fracture risk in this cohort. Although clinical cohort and animal studies suggest a benefit for AChEIs, this was not evident in this study possibly due to clinical cohort limitations. The trend of reduced falls and fracture in the AChEI cohort warrants further study.
- Open Access
- 15 June 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (6) , e70737
Interstitial Lung Disease in Rheumatoid Arthritis: Incidence and Outcomes in Western Australia
Aim: To determine the incidence, risk factors for, and mortality from interstitial lung disease (ILD) in patients with Rheumatoid Arthritis (RA) in Western Australia (WA). Methods: A retrospective statewide cohort study of ILD in patients with RA ( n = 5971) and age/sex matched controls ( n = 20 830) hospitalized between 1985 and 2014. ILD was identified based on validated algorithms. ILD incidence (IR) per 1000 person‐years (PY), odds ratio (OR) for risk factors and respiratory complications, and mortality rate (MR) per 1000 PY were estimated with 95% confidence intervals (CI). Results: The IR of ILD in patients with RA (RAILD+) was increased (IR ratio 8.02, CI 6.28–10.32) and stable over 30 years. Age (OR 1.02, CI 1.01–1.03), smoking (OR 1.97, CI 1.48–2.63), and scleritis (OR 3.84, CI 1.86–7.94) were independent risk factors for ILD. Pulmonary infections, oxygen dependence, and lung cancer occurred as frequently in RAILD+ and CoILD+ but at higher rates than in participants without ILD in each group. MR for RAILD+ patients was higher than for RA patients not developing ILD (99.9 vs. 50.8; p < 0.01), but lower than for CoILD+ (166.3 vs. 99.9, p < 0.01). Conclusion: The incidence of ILD among patients with RA was stably increased over time. ILD increased respiratory morbidity and mortality in both RA and controls. Smoking cessation and early detection could reduce the risk and severity of ILD.
- 15 June 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (6) , e70737
Open AccessInterstitial Lung Disease in Rheumatoid Arthritis: Incidence and Outcomes in Western Australia
Aim: To determine the incidence, risk factors for, and mortality from interstitial lung disease (ILD) in patients with Rheumatoid Arthritis (RA) in Western Australia (WA). Methods: A retrospective statewide cohort study of ILD in patients with RA ( n = 5971) and age/sex matched controls ( n = 20 830) hospitalized between 1985 and 2014. ILD was identified based on validated algorithms. ILD incidence (IR) per 1000 person‐years (PY), odds ratio (OR) for risk factors and respiratory complications, and mortality rate (MR) per 1000 PY were estimated with 95% confidence intervals (CI). Results: The IR of ILD in patients with RA (RAILD+) was increased (IR ratio 8.02, CI 6.28–10.32) and stable over 30 years. Age (OR 1.02, CI 1.01–1.03), smoking (OR 1.97, CI 1.48–2.63), and scleritis (OR 3.84, CI 1.86–7.94) were independent risk factors for ILD. Pulmonary infections, oxygen dependence, and lung cancer occurred as frequently in RAILD+ and CoILD+ but at higher rates than in participants without ILD in each group. MR for RAILD+ patients was higher than for RA patients not developing ILD (99.9 vs. 50.8; p < 0.01), but lower than for CoILD+ (166.3 vs. 99.9, p < 0.01). Conclusion: The incidence of ILD among patients with RA was stably increased over time. ILD increased respiratory morbidity and mortality in both RA and controls. Smoking cessation and early detection could reduce the risk and severity of ILD.
- Open Access
- 12 April 2026
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 13 (3) , 785-797
Frequency and Impact of Serious Infections in Hospitalised Patients with Sjögren’s Disease: A Longitudinal Cohort Study
Introduction As little is known about the risk, type and severity of infections in patients with Sjögren’s disease (SjD), we compared the frequency and impact of serious infections (SI) between hospitalised patients with SjD and controls (Co). Methods Population-level observational study of patients with SjD (n = 692, 87.9% female, age 67 years) identified in the Hospital Morbidity Data Collection (HDMC) in Western Australia (WA) between 1980 and 2015 by diagnostic codes (ICD-9 CM 710.2, ICD10-AM M35.0) and age- and gender-matched controls free of rheumatic disease (n = 3737, 87.5% female, age 67 years). SI were defined by a validated algorithm and primary SjD, as the absence of other autoimmune rheumatic disease. Odds ratios (OR), incidence rates (IR) per 100 person-years (PY) and IR ratios (IRR) with 95% CI for SI were estimated. HDMC data were linked to WA Death Registry to evaluate the impact of SI on mortality rates (MR) per 100 PY and Kaplan–Meier survival estimates. Results Serious infections occurred more in patients with SjD (OR 1.87, CI 1.59, 2.21, p < 0.01) with a fourfold higher IR for SI (IRR 4.28, CI 4.02–4.56) and increased IRR for pneumonia (4.01, CI 3.50–4.60), urogenital (3.06, CI 2.73–3.43), skin/soft tissue (5.22, CI 4.60–5.90), opportunistic infections (6.93, CI 5.77–8.32) and sepsis (6.15, CI 4.87–7.74) (all p < 0.01). The MR for patients with SjD with SI was almost twice that for Co with SI (MR ratio 1.89, CI 1.65–2.16). Patients with associated SjD (n = 270, 39%) had increased OR (2.05, CI 1.49–2.82) and IRR (1.61, CI 1.44–1.79) for SI compared to patients with primary SjD (n = 422, 61%). Few differences in SI existed between patients with SjD associated with rheumatoid arthritis (n = 197) or SLE (n = 79). Conclusions SI occurred at a higher rate in all patients with SjD and was associated with increased long-term mortality. These results emphasize the increased susceptibility to and impact of SI for both patients with primary and secondary SjD.
- 12 April 2026
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 13 (3) , 785-797
Open AccessFrequency and Impact of Serious Infections in Hospitalised Patients with Sjögren’s Disease: A Longitudinal Cohort Study
Introduction As little is known about the risk, type and severity of infections in patients with Sjögren’s disease (SjD), we compared the frequency and impact of serious infections (SI) between hospitalised patients with SjD and controls (Co). Methods Population-level observational study of patients with SjD (n = 692, 87.9% female, age 67 years) identified in the Hospital Morbidity Data Collection (HDMC) in Western Australia (WA) between 1980 and 2015 by diagnostic codes (ICD-9 CM 710.2, ICD10-AM M35.0) and age- and gender-matched controls free of rheumatic disease (n = 3737, 87.5% female, age 67 years). SI were defined by a validated algorithm and primary SjD, as the absence of other autoimmune rheumatic disease. Odds ratios (OR), incidence rates (IR) per 100 person-years (PY) and IR ratios (IRR) with 95% CI for SI were estimated. HDMC data were linked to WA Death Registry to evaluate the impact of SI on mortality rates (MR) per 100 PY and Kaplan–Meier survival estimates. Results Serious infections occurred more in patients with SjD (OR 1.87, CI 1.59, 2.21, p < 0.01) with a fourfold higher IR for SI (IRR 4.28, CI 4.02–4.56) and increased IRR for pneumonia (4.01, CI 3.50–4.60), urogenital (3.06, CI 2.73–3.43), skin/soft tissue (5.22, CI 4.60–5.90), opportunistic infections (6.93, CI 5.77–8.32) and sepsis (6.15, CI 4.87–7.74) (all p < 0.01). The MR for patients with SjD with SI was almost twice that for Co with SI (MR ratio 1.89, CI 1.65–2.16). Patients with associated SjD (n = 270, 39%) had increased OR (2.05, CI 1.49–2.82) and IRR (1.61, CI 1.44–1.79) for SI compared to patients with primary SjD (n = 422, 61%). Few differences in SI existed between patients with SjD associated with rheumatoid arthritis (n = 197) or SLE (n = 79). Conclusions SI occurred at a higher rate in all patients with SjD and was associated with increased long-term mortality. These results emphasize the increased susceptibility to and impact of SI for both patients with primary and secondary SjD.
- Open Access
- 8 April 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (2) , 100159
Temporal incidence and impact of dementia in rheumatoid arthritis: a cohort study
- 8 April 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (2) , 100159
Open AccessTemporal incidence and impact of dementia in rheumatoid arthritis: a cohort study
- Open Access
Dietary Patterns and Cerebral Glucose Metabolism in Older Adults: Findings from the Western Australian Memory Study
Alzheimer’s disease (AD) is characterized by significant reductions in glucose metabolism, reflecting underlying synaptic dysfunction, correlating with cognitive decline. We aimed to explore the impact of dietary patterns on the change in glucose metabolism. Methods: This longitudinal, prospective study included 132 community-dwelling older adults without a diagnosed dementia history enrolled in the Western Australian Memory Study (WAMS). Participants completed a food frequency questionnaire at baseline and underwent [18F]-Fluorodeoxyglucose positron emission tomography (FDG-PET) imaging at baseline and at up to two follow-up assessments scheduled approximately 18 months apart, over a maximum follow-up period of 43 months. Principal component analysis yielded two dietary patterns—named Western Diet and Prudent Diet. Linear mixed-effect models evaluated the association between dietary adherence and glucose metabolism, including potential confounders. Analysis was repeated stratified by sex. Results: Adherence to a Western Diet, characterized by high sugars and saturated fats, was associated with faster decline in glucose metabolism in the left fusiform gyrus (β = −0.00062; SE = 0.00025; FDR-adjusted p = 0.043), neocortex (β = −0.00063; SE = 0.00026; FDR-adjusted p = 0.047), left ventrolateral prefrontal (β = −0.00083; SE = 0.00032; FDR-adjusted p = 0.045 and inferior parietal region (β = −0.00344; SE = 0.00129; FDR-adjusted p = 0.033) in females. A Prudent Diet, characterized by a high intake of fruits, vegetables, and whole grains, showed no significant effects. Conclusions: Our study highlights the following: (a) The potential detrimental impact of a Western Diet on brain glucose metabolism, particularly for females, who are at higher risk for AD. The decline was observed in regions essential for cognitive functions, including visual processing and facial recognition, emphasizing the role of diet in brain health. (b) No significant associations were observed between adherence to a Prudent dietary pattern and changes in glucose metabolism.
Open AccessDietary Patterns and Cerebral Glucose Metabolism in Older Adults: Findings from the Western Australian Memory Study
Alzheimer’s disease (AD) is characterized by significant reductions in glucose metabolism, reflecting underlying synaptic dysfunction, correlating with cognitive decline. We aimed to explore the impact of dietary patterns on the change in glucose metabolism. Methods: This longitudinal, prospective study included 132 community-dwelling older adults without a diagnosed dementia history enrolled in the Western Australian Memory Study (WAMS). Participants completed a food frequency questionnaire at baseline and underwent [18F]-Fluorodeoxyglucose positron emission tomography (FDG-PET) imaging at baseline and at up to two follow-up assessments scheduled approximately 18 months apart, over a maximum follow-up period of 43 months. Principal component analysis yielded two dietary patterns—named Western Diet and Prudent Diet. Linear mixed-effect models evaluated the association between dietary adherence and glucose metabolism, including potential confounders. Analysis was repeated stratified by sex. Results: Adherence to a Western Diet, characterized by high sugars and saturated fats, was associated with faster decline in glucose metabolism in the left fusiform gyrus (β = −0.00062; SE = 0.00025; FDR-adjusted p = 0.043), neocortex (β = −0.00063; SE = 0.00026; FDR-adjusted p = 0.047), left ventrolateral prefrontal (β = −0.00083; SE = 0.00032; FDR-adjusted p = 0.045 and inferior parietal region (β = −0.00344; SE = 0.00129; FDR-adjusted p = 0.033) in females. A Prudent Diet, characterized by a high intake of fruits, vegetables, and whole grains, showed no significant effects. Conclusions: Our study highlights the following: (a) The potential detrimental impact of a Western Diet on brain glucose metabolism, particularly for females, who are at higher risk for AD. The decline was observed in regions essential for cognitive functions, including visual processing and facial recognition, emphasizing the role of diet in brain health. (b) No significant associations were observed between adherence to a Prudent dietary pattern and changes in glucose metabolism.
- 15 November 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Association of Rheumatoid Arthritis With Postfracture Mortality and Fracture-Related Care
Objective: Rheumatoid arthritis (RA) is a potentially devastating autoimmune disease associated with multiple comorbidities, including osteoporosis and cardiovascular disease, which exert significant morbidity and mortality burdens. Despite the recognized connection between RA and fracture risk, few studies have evaluated postfracture survival in RA, and no studies have evaluated the effect of RA on postfracture survival between 1990 and 2010, when there was a rapid growth in disease-modifying antirheumatic drug (DMARD) availability in combination with a paradigm shift in the understanding of RA. Methods: We performed a case-control matched retrospective cohort study of 1304 patients with RA, using routinely collected administrative health data from public and private hospitals in Western Australia, to assess survival after a first fracture. Results: We found that RA associated with a significant survival disadvantage after fracture (hazard ratio [HR] for death 1.28, 95% CI 1.18-1.39). In contrast to expectations, postfracture survival did not improve from 1990-1999 to 2000-2010 in patients with RA or in controls (HR: RA 0.95, 95% CI 0.75-1.20 vs controls 0.86, 95% CI 0.71-1.04). Further, we found that RA is a risk factor for increased episodes of hospital-based care (odds ratio 1.27, 95% CI 1.08-1.48). Conclusion: Using data from hospitals in Western Australia, this study demonstrates that people with RA have worse survival after fracture, and, in contrast to expectation, this survival has not improved despite significant therapeutic advances over the past 40 years. Consequently, this study emphasizes the need to better understand and treat fractures in RA to improve the lives of these patients.
- 15 November 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Association of Rheumatoid Arthritis With Postfracture Mortality and Fracture-Related Care
Objective: Rheumatoid arthritis (RA) is a potentially devastating autoimmune disease associated with multiple comorbidities, including osteoporosis and cardiovascular disease, which exert significant morbidity and mortality burdens. Despite the recognized connection between RA and fracture risk, few studies have evaluated postfracture survival in RA, and no studies have evaluated the effect of RA on postfracture survival between 1990 and 2010, when there was a rapid growth in disease-modifying antirheumatic drug (DMARD) availability in combination with a paradigm shift in the understanding of RA. Methods: We performed a case-control matched retrospective cohort study of 1304 patients with RA, using routinely collected administrative health data from public and private hospitals in Western Australia, to assess survival after a first fracture. Results: We found that RA associated with a significant survival disadvantage after fracture (hazard ratio [HR] for death 1.28, 95% CI 1.18-1.39). In contrast to expectations, postfracture survival did not improve from 1990-1999 to 2000-2010 in patients with RA or in controls (HR: RA 0.95, 95% CI 0.75-1.20 vs controls 0.86, 95% CI 0.71-1.04). Further, we found that RA is a risk factor for increased episodes of hospital-based care (odds ratio 1.27, 95% CI 1.08-1.48). Conclusion: Using data from hospitals in Western Australia, this study demonstrates that people with RA have worse survival after fracture, and, in contrast to expectation, this survival has not improved despite significant therapeutic advances over the past 40 years. Consequently, this study emphasizes the need to better understand and treat fractures in RA to improve the lives of these patients.
- Open Access
- 7 November 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Interstitial lung disease in SLE: a 30-year population study
Objectives: To compare incidence, risk factors and outcomes for interstitial lung disease (ILD) between patients with SLE and controls. Methods: We performed a population-level cohort study using state-wide longitudinal hospital data from Western Australia (WA) for patients with SLE (n = 1854, median age 40 years, 86% female) and matched hospitalized controls (n = 12107, median age 40 years, 88% female) over the period 1985–2014. We estimated ILD incidence rate (IR), determined independent risk factors for ILD using multivariate logistic regression and assessed outcomes including mortality rate (MR) and cause of death. Results presented as median, frequency, IR or MR per 1000 person years (PY) with 95% CIs and IR or MR ratios (IRR or MRR). Results: ILD occurred in 3.8% of SLE patients with a higher IR in SLE than the controls (3.11, 95% CI 2.44–3.91 vs 0.12, 95% CI 0.08–0.16; IRR 26.8) that was stable over time. Time to ILD from index was shorter in SLE and risk factors for ILD included older age, smoking and serositis. SLE-ILD patients experienced higher MRs (MR 52.0, 95% CI 37.0–71.1) than both SLE patients without ILD (MR 17.7, 95% CI 16.0–19.6; MRR 2.94) and controls with ILD (MR 22.8, 95% CI 12.1–38.9; MRR 2.28). ILD decreased survival for SLE and control cohorts and respiratory causes of death predominated in both the ILD groups. Conclusion: ILD occurred more frequently in SLE than the controls with older age, smoking and serositis as risk factors. As SLE-ILD adversely impacts prognosis with increased mortality, greater awareness and earlier management is warranted.
- 7 November 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Open AccessInterstitial lung disease in SLE: a 30-year population study
Objectives: To compare incidence, risk factors and outcomes for interstitial lung disease (ILD) between patients with SLE and controls. Methods: We performed a population-level cohort study using state-wide longitudinal hospital data from Western Australia (WA) for patients with SLE (n = 1854, median age 40 years, 86% female) and matched hospitalized controls (n = 12107, median age 40 years, 88% female) over the period 1985–2014. We estimated ILD incidence rate (IR), determined independent risk factors for ILD using multivariate logistic regression and assessed outcomes including mortality rate (MR) and cause of death. Results presented as median, frequency, IR or MR per 1000 person years (PY) with 95% CIs and IR or MR ratios (IRR or MRR). Results: ILD occurred in 3.8% of SLE patients with a higher IR in SLE than the controls (3.11, 95% CI 2.44–3.91 vs 0.12, 95% CI 0.08–0.16; IRR 26.8) that was stable over time. Time to ILD from index was shorter in SLE and risk factors for ILD included older age, smoking and serositis. SLE-ILD patients experienced higher MRs (MR 52.0, 95% CI 37.0–71.1) than both SLE patients without ILD (MR 17.7, 95% CI 16.0–19.6; MRR 2.94) and controls with ILD (MR 22.8, 95% CI 12.1–38.9; MRR 2.28). ILD decreased survival for SLE and control cohorts and respiratory causes of death predominated in both the ILD groups. Conclusion: ILD occurred more frequently in SLE than the controls with older age, smoking and serositis as risk factors. As SLE-ILD adversely impacts prognosis with increased mortality, greater awareness and earlier management is warranted.
- 1 October 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (1) , 54-61
Long-Term Epidemiology of Systemic Sclerosis in Western Australia: A Population-Level Linked Data Study
Objective: To report the prevalence, incidence and mortality of systemic sclerosis (SSc) in Western Australia (WA). Methods: This was a retrospective observational study, using whole-population linked administrative health data from the WA Rheumatic Disease Epidemiological Registry. All patients with an incident (first-ever) hospitalization with SSc between 1985 and 2013 were identified from discharge diagnosis fields and followed until end of 2014. Outcome measures were incidence rate (IR), point prevalence, standardized mortality ratio (SMR), and survival estimates using Cox regression, stratified by sex. Results: In total 877 patients (mean age 58.6 years, 77.8% female, 3.2% Aboriginal and/or Torres Straits Islander people) had an incident hospitalization for SSc. The age-standardized IR of SSc ranged from 0.44 to 3.26 per 100,000 person-years and point prevalence averaged 37.93 per 100,000 population; both were higher for female individuals. During the study period, 452 (51.5%) patients died with crude mortality higher in male than female patients (66.2% vs 47.4%; P < 0.001). The SMR was 4.17 (95% CI 3.81-4.58), whereas 5- and 10-year survival rates were 67% and 52.4%, respectively. Age (hazard ratio [HR] 1.05, 95% CI 1.04-1.05), male sex (HR 1.56, 95% CI 1.27-1.92), heart failure (HR 1.88, 95% CI 1.36-2.60), kidney disease (HR 1.71, 95% CI 1.13-2.58), and cancer (HR 1.88, 95% CI 1.30-2.74) were independently associated with death. The main causes of death were SSc (n = 128, 28.3%), solid organ malignancy (n = 65, 14.4%), and ischemic heart disease (n = 47; 10.4%). Conclusion: The burden of SSc in WA exceeds global estimates and its high prevalence, high SMR, and number of deaths due to SSc as a primary cause suggest a large unmet therapeutic need.
- 1 October 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (1) , 54-61
Long-Term Epidemiology of Systemic Sclerosis in Western Australia: A Population-Level Linked Data Study
Objective: To report the prevalence, incidence and mortality of systemic sclerosis (SSc) in Western Australia (WA). Methods: This was a retrospective observational study, using whole-population linked administrative health data from the WA Rheumatic Disease Epidemiological Registry. All patients with an incident (first-ever) hospitalization with SSc between 1985 and 2013 were identified from discharge diagnosis fields and followed until end of 2014. Outcome measures were incidence rate (IR), point prevalence, standardized mortality ratio (SMR), and survival estimates using Cox regression, stratified by sex. Results: In total 877 patients (mean age 58.6 years, 77.8% female, 3.2% Aboriginal and/or Torres Straits Islander people) had an incident hospitalization for SSc. The age-standardized IR of SSc ranged from 0.44 to 3.26 per 100,000 person-years and point prevalence averaged 37.93 per 100,000 population; both were higher for female individuals. During the study period, 452 (51.5%) patients died with crude mortality higher in male than female patients (66.2% vs 47.4%; P < 0.001). The SMR was 4.17 (95% CI 3.81-4.58), whereas 5- and 10-year survival rates were 67% and 52.4%, respectively. Age (hazard ratio [HR] 1.05, 95% CI 1.04-1.05), male sex (HR 1.56, 95% CI 1.27-1.92), heart failure (HR 1.88, 95% CI 1.36-2.60), kidney disease (HR 1.71, 95% CI 1.13-2.58), and cancer (HR 1.88, 95% CI 1.30-2.74) were independently associated with death. The main causes of death were SSc (n = 128, 28.3%), solid organ malignancy (n = 65, 14.4%), and ischemic heart disease (n = 47; 10.4%). Conclusion: The burden of SSc in WA exceeds global estimates and its high prevalence, high SMR, and number of deaths due to SSc as a primary cause suggest a large unmet therapeutic need.
- 25 September 2025
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 39 (4) , 102100
Novel therapies in osteoporosis – Clinical update – 2025
- 25 September 2025
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 39 (4) , 102100
Novel therapies in osteoporosis – Clinical update – 2025